Trials / Completed
CompletedNCT04693039
Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets in Patients With Parkinson's Disease in the Early and Middle Stages
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages. 2. To evaluate the pharmacokinetics of Phenlarmide tablets in patients with Parkinson's disease. 3. To explore the efficacy of Phenlarmide tablets in the treatment of early and mid-term Parkinson's disease.
Detailed description
1. Objective to evaluate the tolerance and safety of multiple administration of fenloramide tablets in patients with early and mid-term Parkinson's disease: To evaluate the adverse events of DLT and MTD, adverse reactions, clinical laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, stool routine), vital signs, 12 lead ECG and physical examination of fenloramide tablets in patients with early and mid-term Parkinson's disease . 2. Objective to evaluate the pharmacokinetics of fenloramide tablets in patients with Parkinson's disease in early and middle stages. The main PK parameters included Tmax, SS, Cmax, SS, cavg, SS, Ke, T1 / 2, Cl / F (only fenloramide prototype), VZ / F (only fenloramide prototype), auc0-24, SS, aucinf, SS, auc0 last, SS, AUC\_ %Extrap, DF, etc. 3. Objective to explore the efficacy of fenloramide tablets in the treatment of early and mid-term Parkinson's disease, and to observe the changes of UPDRS and CGI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Phenlarmide | Dosage form:Tablet; Give the medicine once a day,4 weeks is a cycle of administration, a total of 3 cycles of administration. |
| DRUG | Placebo | Dosage form:Tablet; Give the medicine once a day,4 weeks is a cycle of administration, a total of 3 cycles of administration. |
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2021-10-29
- Completion
- 2021-10-29
- First posted
- 2021-01-05
- Last updated
- 2022-01-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04693039. Inclusion in this directory is not an endorsement.